Three Novel Loci Associated With Polycystic Ovary Syndrome ID'd
MONDAY, Dec. 31, 2018 -- Three novel loci have been identified for polycystic ovary syndrome (PCOS), according to research published online Dec. 19 in PLOS Genetics.
Felix Day, Ph.D., from the University of Cambridge School of Clinical Medicine in the United Kingdom, and colleagues performed a meta-analysis of 10,074 PCOS cases and 103,164 controls of European ancestry and characterized PCOS-related traits.
The researchers identified three novel loci and replicated 11 previously identified loci. The genetic architecture was similar for PCOS diagnosed by self-report and for PCOS diagnosed by National Institutes of Health (NIH) or non-NIH Rotterdam criteria across common variants at 13 loci; only one locus differed significantly in its correlation by diagnostic criteria. In affected women, identified variants correlated with hyperandrogenism, gonadotropin regulation, and testosterone levels. There were genetic correlations with obesity, fasting insulin, type 2 diabetes, lipid levels, and coronary artery disease, indicating shared genetic architecture between PCOS and metabolic traits in linkage disequilibrium score regression analysis. Variants associated with body mass index, fasting insulin, menopause timing, depression, and male-pattern balding were suggested to play a causal role in PCOS in Mendelian randomization analyses.
"The genetic underpinnings of PCOS implicate neuroendocrine, metabolic, and reproductive pathways in the pathogenesis of disease," the authors write. "Our findings demonstrate the extensive power of genetic and genomic approaches to elucidate the pathophysiology of PCOS."
Several authors are employees of 23andMe.
© 2020 HealthDay. All rights reserved.
Posted: December 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.